98%
921
2 minutes
20
Aims: To study the correlation between dyspnea, radiological findings, and pulmonary function tests (PFTs) in patients with sequelae of pulmonary tuberculosis (TB).
Materials And Methods: Clinical history, chest computed tomography (CT), and PFT of patients with post-TB sequelae were recorded. Dyspnea was graded according to the Modified Medical Research Council (mMRC) scale. CT scans were analyzed for fibrosis, cavitation, bronchiectasis, consolidation, nodules, and aspergilloma. Semi-quantitative analysis was done for these abnormalities. Scores were added to obtain a total morphological score (TMS). The lungs were also divided into three zones and scores added to obtain the total lung score (TLS). Spirometry was done for forced vital capacity (FVC), forced expiratory volume in 1 s (FEV), and FEV/FVC.
Results: Dyspnea was present in 58/101 patients. A total of 22/58 patients had mMRC Grade 1, and 17/58 patients had Grades 2 and 3 dyspnea each. There was a significant difference in median fibrosis, bronchiectasis, nodules ( < 0.01) scores, TMS, and TLS ( < 0.0001) between dyspnea and nondyspnea groups. Significant correlations were obtained between grades of dyspnea and fibrosis ( = 0.34, = 0.006), bronchiectasis ( = 0.35, = 0.004), nodule ( = 0.24, = 0.016) scores, TMS ( = 0.398, = 0.000), and TLS ( = 0.35, = 0.0003). PFTs were impaired in 78/101 (77.2%) patients. Restrictive defect was most common in 39.6% followed by mixed in 34.7%. There was a negative but statistically insignificant trend between PFT and fibrosis, bronchiectasis, nodule scores, TMS, and TLS. However, there were significant differences in median fibrosis, cavitation, and bronchiectasis scores in patients with normal, mild to moderate, and severe respiratory defects. No difference was seen in TMS and TLS according to the severity of the respiratory defect.
Conclusion: Both fibrosis and bronchiectasis correlated with dyspnea and with PFT. However, this correlation was not linear. The overall extent of radiological abnormalities correlated only with dyspnea but not with PFT.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112814 | PMC |
http://dx.doi.org/10.4103/0970-2113.192871 | DOI Listing |
Front Pharmacol
August 2025
Department of Pharmacy, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Dipeptidyl peptidase 1 (DPP1) inhibitors constitute a major advance in respiratory disease therapeutics. Through selective blockade of neutrophil serine protease (NSP) activation, these agents establish novel treatment paradigms for inflammatory respiratory conditions characterized by neutrophil-driven pathology. This comprehensive review examines the development status, clinical efficacy, and safety profile of DPP1 inhibitors in neutrophil-driven diseases, particularly non-cystic fibrosis bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD).
View Article and Find Full Text PDFCurr Opin Pulm Med
September 2025
Division of Infectious Diseases, Department of Medicine.
Purpose Of Review: Cystic fibrosis (CF) and non-CF bronchiectasis can predispose patients to airway infections that are difficult to treat. The purpose of this review is to discuss recently developed anti-infectives which show promise in treating these infections.
Recent Findings: The microbiology underlying respiratory tract infections in persons with CF (pwCF) and non-CF bronchiectasis is complex.
Curr Opin Pulm Med
September 2025
Division Pediatric Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Purpose Of Review: There is a significant overlap between the diagnostic evaluation for adult and pediatric patients with bronchiectasis; however, also important age-specific unique considerations. This review focuses on these specific considerations.
Recent Findings: Bronchiectasis refers to the radiographic evidence of dilation of distal and proximal bronchi secondary to chronic infection and inflammation.
Lung India
September 2025
Department of Pulmonary Medicine, Apollo Hospitals, Chennai, Tamil Nadu, India.
Bronchiectasis is a chronic airway disease with recurrent exacerbations and hospitalisations. No inhaled antibiotic has shown consistently beneficial effects in trials. This review analyses the evidence on inhaled antibiotics in non-cystic fibrosis bronchiectasis (NCFB), identifies patient traits for their use, and highlights research gaps.
View Article and Find Full Text PDFBMC Pulm Med
September 2025
Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
Background: While Pseudomonas aeruginosa (PA) colonization is linked to poor outcomes in bronchiectasis, emerging evidence suggests that microbial community collapse-marked by diversity loss and depletion of commensal taxa-may better reflect disease progression than pathogen load alone. This study investigates whether airway microbiota dysbiosis driven by PA colonization induces ecological fragility and evaluates the predictive utility of integrating microbial diversity indices with systemic inflammation markers to forecast 1-year acute exacerbation risk using interpretable machine learning.
Methods: Bronchoalveolar lavage fluid (BALF) samples from 23 patients (8 PA-colonized, 15 non-colonized) underwent 16 S rRNA gene sequencing.